Review: Should ethanol be scheduled as a drug of high risk to public health?

Journal of Psychopharmacology

Volumn 23, Issue 1, 2009, Pages 94-100

  Sellman, J D ^a   Robinson, G M ^b   Beasley, R ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WELLINGTON HOSPITAL   (New Zealand)

^c MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

Author keywords

Alcohol; Classification; Drugs of abuse

Indexed keywords

4 HYDROXYBUTYRIC ACID; ALCOHOL; CENTRAL DEPRESSANT AGENT; OXYBATE SODIUM;

ALCOHOL ABUSE; CAUSE OF DEATH; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG MISUSE; HEALTH CARE POLICY; HIGH RISK BEHAVIOR; HUMAN; LAW; LEGAL EVIDENCE; MISUSE OF DRUGS ACT; NEW ZEALAND; PRIORITY JOURNAL; REVIEW; SEDATION; ADDICTION; COMPARATIVE STUDY; DRUG LEGISLATION; GOVERNMENT REGULATION; LEGAL ASPECT; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTOR; STANDARD;

CENTRAL NERVOUS SYSTEM DEPRESSANTS; ETHANOL; GOVERNMENT REGULATION; HUMANS; LEGISLATION, DRUG; NEW ZEALAND; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTORS; SODIUM OXYBATE; SUBSTANCE-RELATED DISORDERS;

EID: 58649089106     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108091596     Document Type: Review

References (53)

1. Abu Bakar, AM (2005) Alcohol - the legal drug of abuse. Professional Bulletin of the National Poison Centre, Malaysia. PRN8099. http:// www.prn2.usm.my/mainsite/bulletin/1995/prn3.html,accesseddate18/5/07.
2. Benzer, TI, Cameron, S., Russi, CS (2005) Toxicity, Gamma Hydroxybutyrate. Emergency Medicine Toxicology, eMedicine. Available at http://emedicine.com/emerg/topic848.htmlastupdatedJanuary82007,accesseddate6/5/ 08.
3. Bloom, FE (2001) Neurotransmission and the central nervous system, Chapter 12. In: Hardman, JG, Limbird, LE, Gilman, AG (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, tenth ed. New York: McGraw-Hill, Medical Publishing Division.
4. Brown, SA, Tapert, SF, Granholm, E., Delis, DC (2000) Neurocognitive functioning of adolescents: Effects of protracted alcohol use. Alcohol Clin Exp Res 24: 164-171.
5. Connor, J., Broad, J., Jackson, R., Vander Hoorn, S., Rehm, J. (2005 a) The burden of death, disease and disability due to alcohol in New Zealand. Wellington, New Zealand: ALAC Occasional Publication No. 23.
6. Connor, J., Broad, J., Rehm, J., Vander Hoorn, S., Jackson, R. (2005 b) The burden of death, disease and disability due to alcohol in New Zealand. N Z Med J 118: 1-12. http://www.nzma.org.nz/journal/118-1213/1412/,accesseddate6/5/ 08.
7. Crome, I., Ghodse, H., Gilvarry, E McArdle (2004) Young People and Substance Misuse. London: Royal College of Psychiatrists.
8. DeBellis, R., Smith, BS, Choi, S., Malloy, M. (2005) Management of delirium tremens. J Intensive Care Med 20: 164-173.
9. De Bonnaire, C., McMillen, P., Lafatelis, E. (2004). The way we drink: the current attitudes & behaviours of New Zealanders (aged 12 plus) towards drinking alcohol. Wellington: Alcohol Advisory Council of New Zealand.
10. Di Castelnuovo, A., Costanzo, S., Bagnardi, V., Donati, MB, Iacoviello, L., de Gaetano, G. (2006) Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med 166: 2437-2445.
11. Dyer, JE, Roth, B., Hyma, BA (2001) Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 37: 147-153.
12. EACD (Expert Advisory Committee on Drugs) (2001) Gammahydroxybutryic acid and related substances ("Fantasy"). Report released December 2001. http://www.moh.govt.nz/moh.nsf/pagescm/569/$File/eacdfantasy.pdf, accesseddate6/5/08.
13. Elliot, SP (2003) Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int 133: 9-16.
14. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2001) Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs, http://www.emcdda.europa.eu/html.cfm/index431EN.html, accesseddate6/5/08.
15. Fleming, M., Mihic, SJ, Harris, RA (2001) Ethanol, Chapter 18. In: Hardman, JG, Limbird, LE, Gilman, AG (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, tenth ed. New York: McGraw-Hill, Medical Publishing Division.
16. Gallimberti, L., Ferri, M., Ferrara, SD, Fadda, F., Gessa, GL (1992) Gamma-hydroxybutyric acid in the treatment of alcohol dependence: A double-blind study. Alcohol Clin Exp Res 16: 673-676.
17. Goldberg, DM, Hahn, SE, Parkes, JG (1995) Beyond alcohol: beverage consumption and cardiovascular mortality. Clin Chim Acta 237: 155-187.
18. Gonzalez, A., Nutt, DJ (2005) Gamma hydroxyl butyrate abuse and dependency. J Psychopharmacol 19: 195-204.
19. Gossop, M. (2006) Classification of illegal and harmful drugs. BMJ 333: 272-273.
20. House of Commons Science and Technology Select Committee (2006) Drug Classification: Making a Hash of It? 5th Report of Session 2005-2006, HC 1031.
21. Inter-Departmental Working Group (1995) Sensible Drinking. London: Department of Health.
22. Jordan, BD (2000) Chronic traumatic brain injury associated with boxing. Semin Neurol 20: 179-185.
23. Kam, PC, Yoong, FF (1998) Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia 53: 1195-1198.
24. Leone, MA, Avanzi, GC, Lo Iacono, A., Vigna-Taglianti, F., Faggiano, F. (2006) Gamma-hydroxybutyrate (GHB) for prevention and treatment of alcohol withdrawal (Protocol). Cochrane Database Syst Rev Issue 4, Art. No: CD006266. DOI: 10.1002/14651858.CD006266.
25. Li, J., Stokes, SA, Woeckener, A. (1998) A tale of novel intoxication: A review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med 31: 729-736.
26. MacDonald, R., Das, A. (2006) UK classification of drugs of abuse: an un-evidence-based mess. Lancet 368: 559-561.
27. MacLennan, FM, Parry, JWL (1983) Gammahydroxybutyrate. Anaesthesia 38: 598-599.
28. Mamelak, M., Scharf, M., Woods, M. (1986) Treatment of narcolepsy with gamma-hydroxybutyrate: a review of clinical and sleep laboratory findings. Sleep 9: 285-289.
29. McIntosh, AS (2005) Rugby injuries. Med Sport Sci 49: 120-139.
30. Mental Health Foundation (2006) Cheers? Understanding the relationship between alcohol and mental health. London: The Mental Health Foundation. http://www.mentalhealth.org.uk/campaigns/mhaw/alcohol,accesseddate6/5/08.
31. Merrick, J., Merrick, E., Morad, M., Kandel, I. (2006) Fetal alcohol syndrome and its long-term effects. Minerva Pediatr 58: 211-218.
32. Murray, CJ, Lopez, AD (1997) Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442.
33. New Zealand Parliament (NZP) (1975). Misuse of Drugs Act (1975) No 116 (as at 01 April 2008), Public Act. http://www.legislation.govt.nz/act/public/ 1975/0116/latest/DLM436101.html?search=ts-act-Misuse+of+Drugs+Act+(1975)&sr= 1, accessed date 6/5/08.
34. New Zealand Parliament (NZP) (1989). Sale of Liquor Act (1989) No 63 (as at 03 September 2007), Public Act. http://www.legislation.govt.nz/act/public/ 1989/0063/latest/DLM165116.html?search=ts-act-Sale+of+Liquor+Act&sr=1, accessed date 6/5/08.
35. Nutt, D. (2006) A tale of two Es. J Psychopharmacol 20: 315-317.
36. Nutt, D., King, LA, Saulsbury, W., Blakemore, C. (2007) Development of a rational scale to assess the harm of drug of potential misuse. Lancet 369: 1047-1053.
37. Oakley-Browne, MA, Wells, JE, Scott, KM, McGee, MA (2006) Lifetime prevalence and projected lifetime risk of DSM-IV disorders in Te Rau Hinengaro: The New Zealand Mental Health Survey. Aust N Z J Psychiatry 40: 865-874.
38. O'Dowd, A. (2006) Tobacco and alcohol should be classed as dangerous drugs. BMJ 333: 275.
39. O'Hagan, J., Robinson, G., Whiteside, E. (1993) Alcohol and Drug Problems: Handbook for Health Professionals. New Zealand: Alcohol Advisory Council of New Zealand, Wellington.
40. Pappas, SC, Silverman, M. (1982) Treatment of methanol poisoning with ethanol and hemodialysis. Can Med Assoc J 126: 1391-1394.
41. Poldrugo, F., Addolorato, G. (1999) The role of gamma-hydroxybutyric acid in the treatment of alcoholism: From animal to clinical studies. Alcohol Alcohol 34: 15-24.
42. Room, R. (2006) The dangerousness of drugs. Addiction 101: 166-168.
43. Room, R., Babor, T., Rehm, J. (2005) Alcohol and public health. Lancet 365: 519-530.
44. Royal College of Psychiatrists (2005) Alcohol: Our favourite drug. London: Mental Health Information, Leaflets Department, The Royal College of Psychiatrists. http://www.rcpsych.ac.uk/mentalhealthinformation/ mentalhealthproblems/alcoholanddrugs/alcoholourfavouritedrug.aspx, accessed date 6/5/08.
45. Schuckit, MA (1995) Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment, fourth ed. New York: Plenum Publishing Corporation.
46. Schuckit, MA, Irwin, M. (1988) Diagnosis of alcoholism. Med Clin North Am 72: 1133-1153.
47. Scott-Ham, M., Burton, FC (2005) Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Forensic Med 12: 175-186.
48. Shannon, M., Quang, LS (2000) Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care 16: 435-440.
49. Smith, LO (2006) Alpine climbing: Injuries and illness. Phys Med Rehabil Clin N Am 17: 633-644.
50. Vickers, MD (1969) Gammahydroxybutyric acid. Int Anesthesiol Clin 7: 75-89.
51. Wells, JE, Oakley-Browne, MA, Scott, KM, McGee, MA, Baxter, J., Kokaua, J. (2006) Prevalence, interference with life and severity of 12 month DSM-IV disorders in Te Rau Hinengaro: The New Zealand Mental Health Survey. Aust N Z J Psychiatry 40: 845-854.
52. Young, R., Feeney, G. (2002) Why do people use drugs? Chapter 2. In: Hulse, G, White, J, Cape, G (eds). Management of Alcohol and Drug Problems. Melbourne: Oxford University Press.
53. Zvosec, DL, Smith, SW, McCutcheon, JR, Spillane, J., Hall, BJ, Peacock, EA (2001) Adverse events, including death, associated with the use of 1, 4 butanediol. N Engl J Med 344: 87-94.